TABLE 2.
Multivariate analyses of progression-free survival and overall survival to assess the impact factor.
| PFS | OS | |||
|---|---|---|---|---|
| HR (95%CI) | p-value | HR (95%CI) | p-value | |
| Age (≤ 60 vs. > 60) | 1.287 (0.753–2.200) | 0.356 | 1.187 (0.682–2.066) | 0.545 |
| Gender (female vs. male) | 0.954 (0.467–1.652) | 0.940 | 0.943 (0.502–1.771) | 0.635 |
| Smoking (no vs. yes) | 0.963 (0.254–3.656) | 0.956 | 0.657 (0.134–2.118) | 0.542 |
| ECOG (0 vs. 1–2) | 0.713 (0.371–1.367) | 0.308 | 0.702 (0.381–1.586) | 0.322 |
| EGFR mutation (21L858 vs. 19del) | 0.670 (0.405–1.108) | 0.118 | 0.684 (0.189–3.909) | 0.146 |
| Brain metastases (none vs. yes) | 0.528 (0.283–0.984) | 0.044 | 0.531 (0.302–1.160) | 0.058 |
| PFS of osimertinib (≤ 6 months vs. > 6 months) | 1.861 (1.099–3.149) | 0.021 | 1.258 (0.807–2.169) | 0.379 |
| Treatment after osimertinib resistance (osi + bev vs. che + bev) | 0.403 (0.233–0.697) | 0.001 | 0.395 (0.225–0.692) | 0.001 |
EGFR, epidermal growth factor receptor; osi + bev, osimertinib plus bevacizumab; che + bev, chemotherapy plus bevacizumab; PFS, progression-free survival; OS, overall survival.